HCV, ribavirin, and anemia: A new dawn

Gastroenterology

Volumn 145, Issue 5, 2013, Pages 930-933

  Pol, Stanislas ^a  

^a INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; BOCEPREVIR; ERYTHROPOIETIN; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ALBUMIN BLOOD LEVEL; ALGORITHM; ANAL COMPLAINT; ANEMIA; BACTERIAL INFECTION; BLOOD TRANSFUSION; CHRONIC HEPATITIS; CLINICAL PRACTICE; COMORBIDITY; DEATH; DISEASE EXACERBATION; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FRANCE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE CYCLE; LIVER CIRRHOSIS; MEDICAL DECISION MAKING; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN TOXICITY; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT OUTCOME; VIRUS HEPATITIS;

EID: 84886801099     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.09.036     Document Type: Editorial

References (20)

1. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis C virus infection J Hepatol 55 2011 245 264
2. M.P. Manns, J.G. McHutchison, and S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
3. L. De Franceschi, G. Fattovich, and F. Turrini Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage Hepatology 31 2000 997 1004
4. J.G. McHutchison, M. Manns, and K. Patel Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
5. J.F. Jen, P. Glue, and S. Gupta Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C Ther Drug Monit 22 2000 555 565
6. J.G. McHutchison, E.J. Lawitz, and M.L. Shiffman Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
7. M.S. Sulkowski, M.L. Shiffman, and N.H. Afdhal Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate Gastroenterology 139 2010 1602 1611
8. N.H. Afdhal Role of epoetin alfa in maintaining ribavirin dose Gastroenterol Clin North Am 33 2004 S25 S35
9. D.T. Dieterich, R. Wasserman, and N. Brau Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa Am J Gastroenterol 98 2003 2491 2499
10. D. Moradpour, F. Penin, and C.M. Rice Replication of hepatitis C virus Nat Rev Microbiol 5 2007 453 463
11. I.M. Jacobson, J.G. McHutchison, and G.M. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
12. F. Poordad, J. McCone, and B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
13. B.R. Bacon, S.C. Gordon, and E. Lawitz Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
14. S. Zeuzem, P. Andreone, and S. Pol Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
15. D. Burger, D. Back, and P. Buggish Clinical management of drug-drug interactions in HCV therapy: challenges and solutions J Hepatol 58 2012 792 800
16. P. Cacoub, M. Bourlière, and J. Lübbe Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals J Hepatol 56 2012 455 463
17. C. Hézode, H. Fontaine, and C. Dorival CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890 J Hepatol 59 2013 434 441
18. M. Sulkowski, K.R. Reddy, and N.H. Afdhal Anemia has no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in ADVANCE and ILLUMINATE phase 3 studies J Hepatol 54 2011 S195
19. F. Poordad, E. Lawitz, and K.R. Reddy Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic Hepatitis C Virus genotype 1 infection - a randomized trial Gastroenterology 145 2013 1035 1044
20. V. Leroy, L. Serfaty, and M. Bourlière Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver Liver Int 32 2012 1477 1492